written on 16.06.2014
Tags:
,

U.K. gatekeepers nix hep C drug Sovaldi till Gilead ponies up more evidence

TAGS: ,

Should the British health service pay for the expensive-yet-effective hepatitis C treatment Sovaldi? The U.K.'s cost-effectiveness gatekeepers say they're not convinced.

Latest Report